Lofgren's syndrome (ICD-11 4B20.Y.5 / ICD-10 D86.9) requires a structured pharmacological approach. This page outlines the therapeutic categories involved; the complete evidence-based regimen is available via the link below.
The protocol involves the addition of a cytotoxic agent, or alternatively, anti-TNF biological therapy. Which agent is selected, how it is sequenced, and the full regimen details are specified in the structured protocol.
Cytotoxic drugs include: methotrexate, azathioprine, mycophenolate and leflunomide.
Anti-TNF therapy includes infliximab and adalimumab.
View source ↗